January 2024 Vol 30.1Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials
Authors: Elliot Dinetz MD, Edwin Lee MD, FACE
Abstract:
Objective • This study aims to assess the safety and efficacy of Thymosin Alpha 1 (Ta1) through a comprehensive narrative review of clinical studies involving over 11 000 human subjects in more than 30 trials. The focus was on Ta1’s application in COVID-19, autoimmune conditions, and cancer treatment, with implications for future considerations.
Methods • We systematically searched articles relevant to critical studies on COVID-19, infectious diseases, cancer, and autoimmune diseases indexed on Pubmed, Google Scholar, and Cochrane Library. Our focus was on evaluating the safety and efficacy of Ta1 in human subjects. Clinical trials conducted worldwide involving diverse populations were analyzed to assess the safety and effectiveness of Ta1. The review examines explicit outcomes in over 11 000 human subjects, emphasizing its role in addressing COVID-19, autoimmune conditions, and cancer treatment.
Results • Contrary to the FDA’s restriction on Ta1 and 21 additional peptides in 2023, our analysis reveals consistent evidence of Ta1’s safety and efficacy. The peptide has demonstrated significant effectiveness in treating various conditions, including COVID-19, autoimmune disorders, and cancer. This review summarizes conclusions drawn from a comprehensive examination of clinical trials worldwide.
Conclusions • Based on substantial evidence from clinical trials, Ta1 emerges as a well-tolerated and effective immune modulator. The FDA›s restriction appears unfounded, as Ta1 has shown safety and efficacy beyond the initially specified conditions. Urgent attention and intervention are warranted to ensure the continued availability of this life-saving peptide through prescription. Therefore, it is recommended that the FDA permits 503A compounding pharmacies to compound Ta1, considering its potential to treat a variety of conditions effectively.
